Blog

How Important is ICER Preparation and Review for U.S. Market Access?
How Important is ICER Preparation and Review for U.S. Market Access? 860 484 Avalon Health Economics LLC

In recent years in the U.S., there has been an increase in the use of cost-effectiveness analysis (CEA) for drug and medical device coverage decisions. While the Center for Medicare and Medicaid Services (CMS) remains considerably behind European countries in the use of CEA in health technology assessment (HTA),1 private health insurers have begun to…

read more

Using Payer Research to Assess Medical Device Market Access
Using Payer Research to Assess Medical Device Market Access 860 484 Avalon Health Economics LLC

Advances in technological innovation and access to capital have recently resulted in a wave of new medical devices, including more accurate diagnostic tools, remote monitoring systems, and automated surgical tools.  This next generation of medical devices has the potential to lower costs and improve outcomes.  Perceptive device makers are taking the time to carefully develop…

read more

Healthcare Use Cases for Blockchain Technology
Healthcare Use Cases for Blockchain Technology 860 484 Avalon Health Economics LLC

Recently, the crypto-currency company Bitcoin has been in the news, mainly for its combination of volatility in valuation coupled with its impenetrable technological foundation.  The virtual currency is perhaps the most well-known application of a technology now commonly referred to as “blockchain.”[1] Each time those Bitcoin stories run, many of us again ask ourselves “what…

read more

Smoke, Mirrors, and Wild Geese: What Should Be the Future Directions of HEOR in the 2020s?
Smoke, Mirrors, and Wild Geese: What Should Be the Future Directions of HEOR in the 2020s? 860 484 Avalon Health Economics LLC

This blog was created from a presentation given at the ISPOR Annual Meeting in New Orleans, May 21st, 2019 as part of an Issues Panel entitled: “Gazing into the HEOR crystal ball: What might the future be for HEOR in the 2020s?”  Thanks must go to my co-presenters: Finn Børlum Kristensen, Nancy Devlin, and Ross…

read more

Avalon Health Economics at the 20th Annual European Conference of ISPOR
Avalon Health Economics at the 20th Annual European Conference of ISPOR 150 150 Avalon Health Economics LLC

In our work in health economics and outcomes research (HEOR) for the life sciences, including biotechnology, pharmaceuticals, and medical devices, we must maintain close ties with our colleagues and stay up to date with the latest thinking on methods of technology assessment, trends in coverage decisions, and relevant changes in the policy and economic environment…

read more

The Value of Biopharmaceutical Innovation in the U.S.
The Value of Biopharmaceutical Innovation in the U.S. 150 150 Avalon Health Economics LLC

There have been some negative reports recently regarding the pricing practices of some pharmaceutical companies. However, it is important to give at least equal consideration to the value derived from the intensive level of research and development undertaken by the biopharmaceutical industry in the U.S. The invention of new products and processes has been shown…

read more

The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research
The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research 150 150 Avalon Health Economics LLC

Although there are a large number of public and private payers in the U.S., medical device and pharmaceutical manufacturers generally focus on two types of payers: (1) Medicare, which is administered by the Centers for Medicare and Medicaid Services (CMS) and covers individuals ages ≥ 65; and (2) private commercial payers (e.g., Blue Cross and…

read more

Will an Unravelling of the Affordable Care Act Result in Meaningful Organizational Changes in U.S. Medical Care? Implications for Economic Evaluation of Drugs & Devices
Will an Unravelling of the Affordable Care Act Result in Meaningful Organizational Changes in U.S. Medical Care? Implications for Economic Evaluation of Drugs & Devices 150 150 Avalon Health Economics LLC

In recent years, there has been a shift in U.S. health care markets to a broader, population-based perspective when assessing the costs and benefits of medical innovation. Cost effectiveness analysis and budget impact analysis results can look quite different when viewed from the perspective of a health system or an accountable care organization, and can…

read more

Medical Device Economics and the Health System Purchaser in the Era of Novel Payment Mechanisms
Medical Device Economics and the Health System Purchaser in the Era of Novel Payment Mechanisms 150 150 Avalon Health Economics LLC

Hospitals in the U.S. spend an estimated 40% of their annual budgets on supplies, medical devices and equipment alone.[1, 2] According to the American Hospital Association, in 2015 total expenditures by U.S. hospitals was $808 billion.[3] That implies that if the 40% supply and equipment estimate is correct, hospitals are spending more than $320 billion…

read more

Value-Based Payment for Oncology Services
Value-Based Payment for Oncology Services 150 150 Avalon Health Economics LLC

Cancer care is a large part of overall health care expenditures. Of the approximately 18% of U.S. gross domestic product spent on healthcare, more than 5% is attributed to cancer treatments.[1] Considering the premature mortality associated with cancer, the humanistic and economic toll is enormous. Consequently, in recent years there has been increasing attention devoted…

read more
Start Typing
Loading...